Vertex Pharmaceuticals was anchored in Cystic Fibrosis and advancing into new frontiers in second-quarter

Overview

In the second quarter of 2025, Vertex Pharmaceuticals delivered solid double-digit revenue growth, fueled by its cystic fibrosis (CF) portfolio and early contributions from three new launches: ALYFTREK®, CASGEVY®, and JOURNAVX®. The company’s commercial execution remained strong both in the U.S. and internationally, supported by robust patient demand, favorable pricing dynamics, and expansion into new geographies.

“Vertex delivered a strong quarter of revenue growth with each of our three product launches — ALYFTREK, JOURNAVX, and CASGEVY — contributing, as well as continued advancement of our clinical programs. As we enter the second half of the year, we are focused on expanding leadership in cystic fibrosis, executing the launches, advancing the pipeline, and preparing for submissions and commercialization in additional disease areas”, said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex.

Q2 2025 vs. Q2 2024:

Total revenue rose to $2.96bn (+12% YoY), driven primarily by continued CF therapy performance and the addition of three ongoing product launches.
- U.S. revenue increased to $1.85bn (+14% YoY), supported by strong patient demand and favorable gross-to-net adjustments versus the prior year.
- International revenue grew $1.12bn (+8% YoY), reflecting solid performance across multiple geographies.
Combined GAAP and non-GAAP R&D, Acquired IPR&D, and SG&A expenses were $1.4bn and $1.2bn, respectively, down from $5.8bn and $5.4bn in Q2 2024. The decline was mainly due to the non-recurrence of $4.4bn in Acquired IPR&D expenses related to the Alpine Immune Sciences acquisition recorded in the prior-year quarter. Expense reductions were partially offset by continued R&D investment in multiple mid- and late-stage programs, and increased commercial spending to support the JOURNAVX® launch.
Effective tax rate was 19.5% (GAAP) and 19.4% (non-GAAP), compared to negative effective tax rates of (6.0%) and (10.0%) in Q2 2024, which reflected the prior-year impact of non-deductible IPR&D charges from the Alpine acquisition.
Net income was $1.0bn (GAAP) and $1.2bn (non-GAAP), compared to net losses of $3.6bn and $3.3bn, respectively, in the year-ago quarter, primarily due to the absence of last year’s Alpine-related charges.
Cash, cash equivalents, and total marketable securities stood at $12.0bn as of June 30, 2025, up from $11.2bn at year-end 2024, reflecting strong operating cash flows partially offset by share repurchases and income tax payments.
CF Franchise ALYFTREK secured new approvals in the EU and Canada and obtained reimbursement agreements, broadening patient access and supporting growth in younger populations.
CASGEVY received approvals in multiple geographies for sickle cell disease and transfusion-dependent beta thalassemia. 115 patients have completed first cell collections, with 29 already infused.
For JOURNAVX, Over 110,000 prescriptions filled since its March launch, now covered for nearly 150m U.S. lives, with steady adoption in targeted hospital systems.

For full-year 2025, Vertex reaffirmed its revenue guidance of $11.85bn to $12.0bn, reflecting expectations for continued growth in its cystic fibrosis portfolio, including the global launch of ALYFTREK®, expanded uptake of CASGEVY® across multiple regions, and early contributions from the U.S. launch of JOURNAVX®. The company also reiterated its outlook for combined GAAP and non-GAAP R&D, Acquired IPR&D, and SG&A expenses, which include ongoing investment in multiple mid- and late-stage clinical programs, commercial capabilities, and approximately $100m in Acquired IPR&D costs. Vertex maintained its non-GAAP effective tax rate guidance of 20.5% to 21.5% and does not expect a material change following the enactment of recent U.S. tax legislation. The guidance also factors in an immaterial cost impact from tariffs in 2025 based on currently known rates and regulations.

Vertex Pharmaceuticals (VRTX) experienced a dramatic -20.6% drop immediately after its earnings release, marking one of its steepest single-day declines in recent memory. While the downward momentum persisted, the pace of the sell-off eased slightly toward the end of the trading week, yet the stock still posted a sharp -21% loss over the past five sessions. Year-to-date, after a partial recovery earlier in the year, particularly following the post-earnings drop in May, the stock has now slid to fresh 52-week lows, breaking decisively below both its 50-day ($450.99) and 200-day ($461.38) moving averages. The RSI at 26.38 signals deeply oversold conditions, which could potentially lead to a short-term technical rebound, though the broader trend remains firmly bearish unless the price can reclaim key resistance levels.